Excellence in Oncology Care Shares 5-Year KN564 Data on Adjuvant Pembrolizumab in RCC

Excellence in Oncology Care – EIOC posted on X:

“5 year follow up for adjuvant pembro in RCC (KN564). DFS (5yr 52% v61% – HR0.71). OS (5yr 82% vs 88% HR0.66). Maintained KM curve separation.”